CorVista System with PH Add-On

by Analytics for Life  · Based in Canada →Pioneering non-invasive diagnostic solutions for cardiovascular diseases through the CorVista System®.
Cardiology Internal Medicine Pulmonology

Contact for pricing
Regulatory Status Disclosed

Overview

The CorVista System with PH Add-On, developed by Analytics for Life, is an FDA-cleared, non-invasive cardiovascular diagnostics platform. It utilizes proprietary machine-learned algorithms to analyze cardiac and hemodynamic signals, providing rapid, point-of-care insights into a patient’s cardiovascular health. The system is designed to aid in the diagnosis of significant coronary artery disease (CAD) and pulmonary hypertension (PH) without requiring radiation, contrast agents, injections, fasting, or exercise. Its modular design allows for the integration of disease-specific add-ons, expanding its diagnostic capabilities. The CorVista System delivers actionable diagnostic insights within minutes, accessible via a secure web portal, aiming to improve early detection and patient management in various care settings, including underserved and rural areas.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Non-invasive cardiovascular diagnostics
  • Point-of-care testing
  • Machine-learned algorithms for analysis
  • Analyzes cardiac and hemodynamic signals
  • No radiation, contrast agents, injections, fasting, or exercise required
  • Rapid results available within minutes
  • Secure web portal for physician access to analysis
  • Modular design with disease-specific add-ons (CAD, PH)
  • Aids in diagnosis of Coronary Artery Disease (CAD)
  • Aids in diagnosis of Pulmonary Hypertension (PH)

Use Cases

  • Aid in the diagnosis of Coronary Artery Disease (CAD)
  • Aid in the diagnosis of Pulmonary Hypertension (PH)
  • Early detection and triage of patients with cardiovascular symptoms
  • Extending advanced cardiology diagnostic services to underserved and rural areas
  • Reducing the need for more invasive diagnostic procedures
  • Potential for early detection of heart failure (investigational)

What Physicians Need to Know

ECG/EKG Analysis Capability
The CorVista System analyzes synchronously acquired cardiac electrical signals (via VCG in orthogonal axes) and hemodynamic signals (via photoplethysmography (PPG)) to measure electrical activity and blood flow.
Heart Failure Risk Prediction
The system is being developed to assess elevated pulmonary capillary wedge pressure (PCWP) and left ventricular end-diastolic pressure (LVEDP), which are indicators of heart failure. A developmental model showed potential as an effective rule-out test for heart failure with high sensitivity (90% for PCWP, 92% for LVEDP u226525 mmHg) and negative predictive value (99.5% for LVEDP u226525 mmHg).
Coronary Artery Assessment
The CorVista System with the CAD Add-On is FDA-cleared to evaluate the presence of significant coronary artery disease (CAD) as an aid in diagnosis, demonstrating a 99% negative predictive value for ruling out significant CAD. It also shows potential for detecting Ischemia with Non-Obstructive Coronary Arteries (INOCA).
Pulmonary Hypertension Diagnosis
The PH Add-On is FDA-cleared and indicates the likelihood of elevated mean pulmonary arterial pressure (mPAP), a key indicator of pulmonary hypertension (PH). It has demonstrated 82% sensitivity and 92% specificity for detecting mPAP u226525 mmHg, and can detect PH even when traditional echocardiography fails.
Real-Time Alert Capability
The system provides diagnostic results within minutes, available in a secure web portal, to aid physicians in rapid diagnosis and treatment decisions at the point of care.
AHA/ACC Guideline Alignment
Clinical utility has been showcased in the Journal of the American College of Cardiology (JACC), and its diagnostic performance for PH is comparable to or surpasses current standard-of-care modalities. New data on cardiac ischemia detection was presented at the American College of Cardiology's Annual Scientific Session (ACC.26).
Physician Tip

The CorVista System with PH Add-On offers a non-invasive, rapid, point-of-care solution for diagnosing coronary artery disease and pulmonary hypertension, and shows promise for heart failure assessment. It can be particularly valuable for early detection, triaging patients for more invasive procedures, and reducing diagnostic delays, especially in cases where traditional methods like echocardiography are inconclusive or unavailable. Its ability to provide results within minutes can significantly streamline clinical workflows and facilitate timely treatment decisions.

The CorVista System operates as a 'MedTech-as-a-Service' model, utilizing a cloud-based AI/ML algorithm for analysis. Physiological signals are collected by a portable device, sent to secure cloud databases for processing, and a physician diagnostic report is automatically pushed back to the doctor's office. The system is designed as a platform with a modular design, allowing for the integration of additional AI/ML cardiovascular disease detection algorithms or 'Add-ons' over time.

Details

Category Cardiology AI, Radiology & Imaging AI
Pricing Contact for pricing
DeploymentCloud-based (data collected at point-of-care, processed in the cloud, results via secure web portal).
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

The CorVista System with CAD Add-On received FDA 510(k) clearance in September 2023 for evaluating the presence of significant coronary artery disease. The CorVista System with Pulmonary Hypertension (PH) Add-On Module received FDA clearance in April 2024 for indicating the likelihood of elevated mean arterial pulmonary pressure (mPAP), an indicator of pulmonary hypertension. The PH Add-On also received Breakthrough Device Designation in 2022.

Integrations
EHR Not specified
Specialties Cardiology, Internal Medicine, Pulmonology

What the Web Says

The CorVista System with PH Add-On is a non-invasive, machine-learned, point-of-care diagnostic tool cleared by the FDA to aid in the early detection of pulmonary hypertension (PH) and coronary artery disease (CAD). It uses AI-based algorithms to analyze cardiac and hemodynamic signals, providing results within minutes without the need for radiation, contrast agents, injections, fasting, or exercise. Physicians and medical professionals generally view the system positively due to its potential to shorten diagnostic pathways and improve patient outcomes, especially in underserved areas.

Overall: Positive

Strengths

  • Non-invasive and rapid, providing results within minutes at the point of care.
  • Aids in earlier diagnosis of pulmonary hypertension and coronary artery disease, potentially improving patient outcomes.
  • Utilizes machine learning and AI for precise and reliable diagnostic insights.
  • Can be used in low-resource and rural settings, increasing access to advanced cardiovascular diagnostics.
  • Demonstrated high sensitivity (82%) and specificity (92%) for detecting elevated mean pulmonary arterial pressure (mPAP).
  • Reduces the need for multiple specialist visits and invasive procedures like right heart catheterization.

Limitations

  • No specific negative reviews or opinions from physicians, healthcare IT, tech reviewers, Reddit, G2, or Capterra were found in the search results.
  • As a relatively new technology, long-term real-world effectiveness and integration into broader healthcare systems are still being established.
  • The anticipated PCWP Add-On algorithm is currently under FDA review and not commercially available.
  • While a Category III CPT code has been granted, it is a temporary code for emerging technologies, and a clear reimbursement pathway is still developing.

Based on reviews from: Financial Post, Clinical Lab Products, accessdata.fda.gov, Pulmonary Hypertension News, Diagnostic and Interventional Cardiology, Business Wire, MedicaEx.com, YouTube (The Planetary Health First Mars Next podcast), Medical Technology Enterprise Consortium (MTEC), PMC (PubMed Central), BioWorld

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate CorVista System with PH Add-On

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

MPO (Medical Product Outsourcing)
CorVista System with Pulmonary Hypertension Add-On Cleared by FDA
Analytics for Life Inc. and CorVista Health Inc. received FDA clearance for the CorVista System with Pulmonary Hypertension (PH) Add-On Module, making it the first FDA-cleared, machine-learned point-of-care technology for indicating the likelihood of elevated mean arterial pulmonary pressure. This non-invasive system aims to enable earlier diagnosis and better patient experiences in PH detection and treatment.
2024-05
BioSpace
Breakthrough Designated CorVistau00ae System with Pulmonary Hypertension Add-On Cleared by FDA; Enabling Advanced Cardiovascular Testing at Point-of-Care
Analytics for Life, Inc. and CorVista Health Inc. announced FDA clearance of the CorVista System with Pulmonary Hypertension (PH) Add-On Module, a breakthrough-designated device. This system is the first FDA-cleared, machine-learned point-of-care technology for indicating the likelihood of elevated mean arterial pulmonary pressure, expanding diagnostic capabilities for cardiovascular conditions.
2024-04
Clinical Lab Products
Advanced Cardiovascular POC Testing System Gets FDA Clearance
Analytics for Life and CorVista Health have received U.S. FDA clearance for the CorVista System with Pulmonary Hypertension (PH) Add-On Module. This system is a machine-learned, point-of-care technology designed to indicate the likelihood of elevated mean arterial pulmonary pressure, addressing the challenge of early PH diagnosis.
2024-04
Financial Post
Breakthrough Designated CorVistau00ae System with Pulmonary Hypertension Add-On Cleared by FDA; Enabling Advanced Cardiovascular Testing at Point-of-Care
The CorVista System with Pulmonary Hypertension (PH) Add-On Module has received FDA clearance, marking it as the first FDA-cleared, machine-learned point-of-care technology for indicating the likelihood of elevated mean arterial pulmonary pressure. This clearance follows its 2022 Breakthrough Device designation and aims to improve early diagnosis of PH.
2024-04
Business Wire
Breakthrough Designated CorVistau00ae System with Pulmonary Hypertension Add-On Cleared by FDA; Enabling Advanced Cardiovascular Testing at Point-of-Care
Analytics for Life, Inc. and CorVista Health Inc. announced FDA clearance for the CorVista System with Pulmonary Hypertension (PH) Add-On Module. This is the second FDA clearance for the CorVista System, expanding its diagnostic capabilities for cardiovascular conditions using a proprietary machine learning algorithm.
2024-04
PMC (PubMed Central)
Machine Learning-Enabled Medical Devices Authorized by the US Food and Drug Administration in 2024: Regulatory Characteristics, Predicate Lineage, and Transparency Reporting
This peer-reviewed article, published in December 2025, includes the CorVista System with PH Add-On (K233666) as one of the machine learning-enabled medical devices authorized by the FDA in 2024. It highlights the device's 510(k) regulatory pathway and its application in pulmonary hypertension assessment with reported sensitivity and specificity.
2025-12
accessdata.fda.gov
Analytics for Life, Inc. Gabrielle Zaeska Vice President, Regulatory Affairs and Quality First Canadian Place 100 King Street We
This FDA 510(k) clearance document details the CorVista System with PH Add-On, confirming its safety and effectiveness through validation testing. It describes the system's architecture, which integrates with add-ons for disease-specific analysis using machine-learned detection algorithms.
2023-11
X-ray Interpreter
CorVista System with PH Add-On
The CorVista System with PH Add-On is described as a non-invasive, AI-based medical device cleared by the FDA that analyzes cardiac electrical and hemodynamic signals to indicate the likelihood of elevated pulmonary arterial pressure, assisting clinicians in diagnosing pulmonary hypertension.
2024-04

Videos

Product demos, reviews, and walkthroughs for CorVista System with PH Add-On.

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

The CorVista System with PH Add-On is a non-invasive, point-of-care solution designed to indicate the likelihood of elevated mean arterial pulmonary pressure (mPAP) within minutes. It collects physiological signals at rest, providing results in a secure web portal to aid in earlier diagnosis and patient triage, complementing existing diagnostic pathways.
The CorVista System utilizes machine-learned algorithms to analyze cardiac and hemodynamic signals, generating a score indicating the likelihood of pulmonary hypertension. Physicians should interpret these results in conjunction with their clinical judgment, the patient's signs, symptoms, and clinical history, as the system serves as an aid in diagnosis, not a standalone diagnostic tool.
The CorVista System with PH Add-On received FDA clearance in April 2024, following its Breakthrough Device Designation in 2022. The system operates on a medical-device-as-a-service model, processing data in the cloud and making results available in a secure web portal, implying robust measures for protected health information.
While highly sensitive and specific for elevated mPAP, the CorVista System is an aid to diagnosis and does not replace the gold standard of invasive right heart catheterization. Its effectiveness in specific, rare PH subtypes or complex comorbidities would need careful consideration, though studies show consistent performance across various subgroups.
The CorVista System offers a non-invasive, rapid point-of-care alternative to traditional screening methods like transthoracic echocardiography (TTE), which can have limitations in visualizing key parameters. While not replacing invasive right heart catheterization (RHC), it aims to enable earlier detection of PH, potentially reducing the need for multiple inconclusive tests and specialist referrals.
Specific pricing details are not publicly disclosed, but the CorVista System operates on a 'medical-device-as-a-service' model. This approach suggests a subscription or per-use fee, potentially offering cost-effectiveness by enabling earlier, non-invasive diagnosis at the point of care, which could reduce subsequent invasive procedures and specialist visits.

Related Tools

Cardiomatics
Cardiomatics
Cardiology AI
Cardiomatics is a cloud-based, AI-powered software for analyzing ambulatory (Holter) ECG tests, using clinically validated algorithms to provide accurate and high-quality results for cardiac diagnostics. It aims to streamline ECG analysis, reduce interpretation time, and improve diagnostic accuracy for various heart conditions.
SafeBeat Rx App
SafeBeat Rx, Inc.
Cardiology AI
An AI application designed to support safe pharmacological treatment and monitoring for cardiac arrhythmias.
PreemptiveAI Clinical SDK
Measure Labs, Inc. (Dba Preemptiveai, Inc.)
Cardiology AI
A clinical software development kit using AI to model and predict cardiovascular health metrics, aiming to shift healthcare from reactive to proactive by providing early health risk signals.
Clarius Ejection Fraction AI
Clarius Mobile Health Corp.
Cardiology AI
Clarius Ejection Fraction AI is an AI-powered ultrasound tool for automated left ventricular ejection fraction calculation, integrated into the Clarius Ultrasound App for real-time cardiac assessments.
Automated Aortic Stenosis Software (AutoAS)
Multiple companies are developing Automated Aortic Stenosis Software (AutoAS) or similar AI-powered solutions. Notable ones include iCardio.ai, Us2.ai, AccurKardia, HeartSciences Inc., and Echo IQ.
Cardiology AI
Automated Aortic Stenosis Software (AutoAS) is an ultrasound application by GE Medical Systems that provides automated assessment of aortic stenosis to enhance diagnostic efficiency and consistency.
ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm
Anumana
Cardiology AI
An AI algorithm that analyzes standard 12-lead ECG recordings to detect signs of pulmonary hypertension, aiming for earlier diagnosis and improved patient outcomes.

See all Cardiology AI tools →

Suggest an Edit → | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.